Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)

v3.23.2
Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2022
Jun. 30, 2023
Jun. 30, 2023
Agreements      
Short-term royalty receivable, Balance at beginning of period     $ 2,366
Short-term royalty receivable, Balance at end of period   $ 4,958 4,958
Long-term royalty receivable, Balance at beginning of period     63,683
Impairment of royalty and commercial payment rights, Long-Term   (1,575) (1,575)
Long-term royalty receivable, Balance at end of period   $ 72,232 72,232
Affitech      
Agreements      
Receipt of royalty and commercial payments, Short-Term     (2,366)
Reclassification to short-term royalty and commercial payment receivables, Short-Term     4,958
Reclassification to short-term royalty and commercial payment receivables, Long-Term     (4,958)
Aptevo      
Agreements      
Acquisition of royalty and commercial payment rights, Long-Term     9,650
Receipt of royalty and commercial payments, Long-Term     (568)
LadRx      
Agreements      
Acquisition of royalty and commercial payment rights, Long-Term     6,000
Bioasis      
Agreements      
Impairment of royalty and commercial payment rights, Long-Term     $ (1,575)
Royalty Purchase Agreement | Kuros      
Agreements      
Receipt of royalty and commercial payments, Long-Term $ (2,500)